Celularity Sets Dec 30 Vote on Nasdaq Share Issuance, With 10% Price Cut if Rejected
CELU sits 29% above its 52-week low of $0.56.
Summary
Celularity's definitive proxy for its December 30, 2026 annual meeting asks holders to approve the full share issuance under the September 2026 convertible financing; rejection by December 19, 2026 triggers a 10% cut to note conversion and warrant exercise prices. A separate proposal adds 3,500,000 shares to the 2021 equity plan.
Key Events · Corporate Governance and Compliance · CELU
-
Nasdaq Share Issuance Vote Set
Proposal 6 seeks approval, for Nasdaq Listing Rule 5635, of the full issuance of Class A common stock upon conversion of notes and exercise of warrants under the September 23, 2026 Securities Purchase Agreement, including shares for accrued interest and adjustment provisions.
-
10% Price Cut if Vote Fails
If the required stockholder approval is not obtained on or prior to December 19, 2026, the then-current conversion price of each outstanding Note and exercise price of each outstanding Warrant automatically drops 10%, effective December 20, 2026 — increasing the share count behind the same principal.
-
Equity Plan Reserve Raised 3.5M Shares
Proposal 5 would increase the 2021 Equity Incentive Plan reserve by 3,500,000 shares to 4,479,204 total; only 1,715,541 shares remained available as of the record date.
-
Meeting December 30, Record Date Nov 9
The annual meeting is December 30, 2026 at 1:00 p.m. Eastern at the Florham Park headquarters; holders of record as of November 9, 2026 vote, with 32,450,679 Class A shares outstanding.
Analysis · CELU · Life Sciences
Proposal 6 is the vote that matters: it seeks approval, for Nasdaq Rule 5635 purposes, of the full share issuance under the September 23, 2026 convertible note and warrant package. Should holders fail to approve by December 19, 2026, every outstanding note conversion price and warrant exercise price drops 10% effective December 20, 2026 — more shares for the same principal, and more dilution. Against a going-concern backdrop with $0.6M of cash, that is a real cost of a failed vote. Proposal 5 adds 3,500,000 shares to the 2021 Equity Incentive Plan (to 4,479,204 total), with only 1,715,541 shares left available as of the record date, so the compensation pool is nearly exhausted. The rest — director election, auditor ratification, say-on-pay — is routine.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.1M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.